XGN (Exagen) Valuation Rank


XGN Exagen Inc XGN
60 GF Score
Price $4.54
GF Value $3.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exagen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Exagen Valuation Rank Related Terms

XGN
60GF Score
Exagen Inc XGN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $4.54 is trading 51.3% above its estimated GF Value™ of $3.00. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Valuation Rank:
  • GF Value™: $3.00 vs. price of $4.54 (51.3% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
60GF Score

Get the complete analysis for XGN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.54
Price
$3.00
GF Value